APPLICATION DOPAMINE AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME


如何引用文章

全文:

详细

Restless legs syndrome (RLS) is one of the most common human diseases occurring in 2-5% of the adults. Clinical manifestation of RLS is sense of discomfort in the legs that appear in the evening and night time - usually at rest, and force the patient to make movements by legs, which lead to the temporary elimination of discomfort. The main complications of RLS are nocturnal sleep dysfunction, daytime sleepiness, psychoemotional disorders, and increased risk of cardiovascular disease. Dysfunction of dopaminergic systems, particularly diencephalospinal pathway is underlying mechanism of RLS, which is exacerbated by iron deficiency or other factors in some cases. The use of dopamine agonists (DA) allows to quickly normalize the patient's condition. For many years, DAs are still effective in patients with RLS, and these drugs are the basis for long-term therapy of this syndrome.

参考

  1. Аверьянов Ю.Н., Подчуфарова Е.В. Синдром беспокойных ног // Неврологический журнал. 1997. № 3. С. 12-16.
  2. Левин О.С. Синдром беспокойных ног. Экстрапирамидные расстройства. Руководство по диагностике и лечению / Под ред. В.Н. Штока, И.А. Ивановой-Смоленской, О.С. Левина. М., 2002. С. 425-434.
  3. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739.
  4. Akyol A, Kiylioglu N, Kadikoylu G, et al. Iron deficiency anemia and restless legs syndrome: Is there an electrophysiological abnormality? Clin Neurol Neurosurg 2003;106:23-27.
  5. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.
  6. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
  7. Allen RP. Contraversies and challenges in defining etiology and pathophysiology of restless legs syndrome. Am J Med 2007;120:S.13-21.
  8. Brindani F, Vitetta F, Gemignani F. Restless legs syndrome: differential diagnosis and management with pramipexole. Clin Interventi Aging 2009;4:305-13.
  9. Вrodeur C, Montplaisir J, Godbout R, et al. Treatment of restless legs syndrome and periodic movements during sleep with L-DOPA: a double-blind, controlled study. Neurology 1988;38:1845-48.
  10. Clemens S, Rye D, Hochman S. Restless legs syndrome. Revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006;67:125-30.
  11. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo controlled trial. Sleep Med 2008;9:874-81.
  12. Garcia-Borreguero D., Allen R.P., Kohnen R. et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine - International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30.
  13. Hening WA, Allen RP, Chokroverty S, et al. Restless legs syndrome. Phyladelphia: Saunders 2009:312 P.
  14. Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multicenter study. J Neurol 2010;257:230-37.
  15. Kaplan PW, Allen RP, Buchholz DW, et al. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23.
  16. Lin SC, Kaplan J, Burger CD, et al. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998;73:497-500.
  17. Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic legs movements. Sleep Med 2007;8:491-97.
  18. Montplaisir J, Lapierre O, Warnes H, et al. The treatment of the restless leg syndrome with or without periodic leg movements in sleep. Sleep 1992;15(5):391-95.
  19. Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole. Neurology 1999;52:938-43.
  20. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(Suppl. 1):S.27-31.
  21. Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-11.
  22. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-19.
  23. Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007;22(Suppl.):S.466-75.
  24. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of Pramipexole in idiopathic restless legs syndrome: A polysomnographic dose finding study - The PRELUDE study. Sleep Med 2006;7:407-17.
  25. Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of Pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Med 2008;9:537-41.
  26. Paulus W, Trenkwalder C. Pathophysiology of dopaminergic therapy - related augmentationin restless legs syndrome. Lancet Neurology 2006;5:878-86.
  27. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-26.
  28. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. Neuropsychobiology 2004;50:65-70.
  29. Trenkwalder C, Stiasny-Kolster K, Kupsch ., et.al. Controlled withdrawal of pramipexole after 6 months of open label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-10.
  30. Trenkwalder C, Henning WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Movement Disorders 2008;23:2267-02.
  31. Trenkwalder C, Hogl B, Benes H, et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008;9:572-74.
  32. Winkelman JW, Shahar E, Sharief I, et al. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35-42.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##